Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teverelix TFA in Advanced Prostate Cancer
NCT04693507Phase 2Completed
- Sponsor
- Antev
- Start
- Mar 2021
- Primary completion
- Dec 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of teverelix in prostate cancer (PCa), sponsored by Antev. Started Mar 2021; status: completed.
02
Drugs
teverelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04693507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04693507.